Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: A meta-analysis of randomized controlled clinical trials

Archives of Internal Medicine

Volumn 156, Issue 20, 1996, Pages 2321-2332

  Koch, Maurizio ^a   Dezi, Angelo ^a   Ferrario, Fabio ^a   Capurso, Lucio ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; DICLOFENAC; DIFLUNISAL; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PIROXICAM; RANITIDINE; SULINDAC; TOLMETIN;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG INDUCED DISEASE; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; ULCER HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS; STOMACH ULCER; TIME FACTORS;

EID: 0029854798     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.20.2321     Document Type: Article

References (77)

1. Baum C, Kennedy DL, Forbes MB. Utilisation of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1985;28:686-692.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature. 1971;231:232-235.
3. Fries JF. Postmarketing drug surveillance: are our priorities right? J Rheumatol. 1988;15:389-390.
4. Roth SH. Non-steroidal anti-inflammatory drug gastropathy: we started it - can we stop it? Arch Intern Med. 1986;146:1075-1076.
5. Zeidler H. Epidemiology of NSAID-induced gastropalhy. J Rheumatol. 1991; 18(suppl 28):2-5.
6. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? epidemiology and risk appraisal. J Rheumatol. 1991;18(suppl 28):6-10.
7. Carson JL, Strom BL, Morse ML. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987;147:1054-1059.
8. Redfern JS, Lee E, Feldman M. Effect of immunisation with prostaglandin metabolites on gastrointestinal ulceration. Am J Physiol. 1988;255:723-730.
9. Shorrock CJ, Rees WDW. Overview of gastroduodenal mucosal protection. Am J Med. 1988;84(suppl 2A):25-34.
10. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277-1280.
11. Lanza F. A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci. 1986;31(February suppl):131S-136S.
12. Aadland E, Fausa O, Vatn M, Chen H, Quinlan D. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med. 1987;83(suppl 1A):37-40.
13. Lanza FL, Aspinall RL, Swabb EA, Davis RE, Rack MF, Rubin A. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology. 1988;95:289-294.
14. Lanza F, Peace K, Gustitus L, Rack MF, Dickson B. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol. 1988;83:143-146.
15. Jiranek GC, Kimmey MB, Saunders DR, Willson RA, Shanahan W, Silverstein FE. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology. 1989;96:656-661.
16. Lanza FL, Fakouhi D, Rubin A, et al. A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 μg of misoprostol qid in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms. Am J Gastroenterol. 1989;84:633-636.
17. Saggioro A, Alvisi V, Blasi A, Dobrilla G, Fioravanti A, Marcolengo R. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis, Ital J Gastroenterol. 1991;23:119-123.
18. Geis GS, Stead M, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol. 1991;18(suppl 28):11-14.
19. Lanza FL, Kochman RL, Geis GS, Rack EMF, Deysach LG. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol. 1991;86:1743-1748.
20. Verdickt W, Moran C, Hantzschel H, Fraga AM, Stead H, Geis GS. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol. 1992;21:85-91.
21. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute nonsteroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol. 1993;32:990-995.
22. Elliot SL, Yeomans ND, Buchanan RRC, Smallwood R. Efficacy of 12 months' misoprostol as prophylaxis against NSAIO-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol. 1994;23:171-176.
23. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119:257-262.
24. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulcers. Gut. 1991;32:252-255.
25. Tildesley G, Ehsanullah RSB, Wood JR. Ranitidine in the treatment of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1993;32:474-478.
26. Stiel D, Ellard KT, Hills LJ, Brooks PM. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man: comparison with cimetidine and sucralfate. Am J Med. 1986;31(suppl 2A):54-58.
27. Berkowitz JM, Adler SN, Sharp JT, Warner CW. Reduction of aspirin-induced gastroduodenal mucosal damage with ranitidine. J Clin Gastroenterol. 1986; 8:377-380.
28. Berkowitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med. 1987;147:2137-2139.
29. Bianchi Porro G, Pace F, Caruso I. Why are non-steroidal anti-inflammatory drugs important in peptic ulceration? Aliment Pharmacol Ther. 1987;1:540S-547S.
30. Stalnikowicz R, Pollack D, Eliakim A, et al. Cimetidine decreases indomethacin-induced duodenal mucosal damage in patients with acute musculoskeletal disorders. Gut. 1988;29:1578-1582.
31. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988;297:1017-1021.
32. Stalnikowicz R, Goldin E, Fich A, et al. Indomethacin-induced gastroduodenal damage is not affected by cotreatment with ranitidine. J Clin Gastroenterol. 1989;11:178-182.
33. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34:424-428.
34. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury: effect of scoring method. Dig Dis Sci. 1990;35:1494-1499.
35. Data on file (Glaxo Inc. Research Triangle Park, NC). Cited by: Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with nonsteroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther. 1991;5: 143-150.
36. Cole AT, Brundell S, Hudson N, Hawthorne AB, Mahida YR, Hawkey CJ. Ranitidine: differential effects on gastric bleeding and mucosal damage induced by aspirin. Aliment Pharmacol Ther. 1992;6:707-715.
37. Levine LR, Michelle LC, Nathana HE. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993;153:2449-2454.
38. French PC, Darekar BS, Mills JG, Wood JR. Ranitidine in the prevention of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulceration in arthritic patients. Eur J Gastroenterol Hepatol. 1994;6:1141-1147.
39. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analysis of randomized clinical trials. N Engl J Med. 1987;316:224-233.
40. Chalmers TC, Buyse ME. Meta-analysis. In: Chalmers TC, Blum A, Buyse M, Hewitt P, Koch M, eds. Data Analysis for Clinical Medicine: the Quantitative Approach to Patient Care in Gastroenterology. Rome, Italy: International University Press; 1988:75-84.
41. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
42. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Towards an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology. 1989;96:647-655.
43. Jones MP, Schubert ML, Smith JL. What do you recommend for prophylaxis in an elderly woman with arthritis requiring NSAIDs for control? Am J Gastroenterol. 1991;86:264-268.
44. UCLA conference. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991;114:307-319.
45. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal anti-inflammatory drug therapy. Gastroenterology. 1989;96:675-681.
46. Zeidler H, Munzel P. NSAIDs: new approaches to limiting gastropathy. Scand J Rheumatol. 1989;(suppl 78):18-23.
47. Fenn GC, Robinson GC. Misoprostol - a logical therapeutic approach for gastroduodenal mucosal injury induced by non-steroidal anti-inflammatory drugs? J Clin Pharm Ther. 1991;16:385-409.
48. Yanagawa A, Endo T, Nakagawa T, Misushima Y. Prophylactic efficacy of ranitidine against gastroduodenal mucosal damage from non-steroidal anti-inflammatory drugs: a randomized placebo-controlled study: arthritis and the GI tract. Round Table Series. 1990;21:97-103.
49. Hudson N, Murray FE, Cole AT, Turnbull GM, Lettis S, Hawkey CJ. Ranitidine bismuth citrate and aspirin-induced gastric mucosal injury. Aliment Pharmacol Ther. 1993;7:515-521.
50. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31-49.
51. Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol. 1986:4:942-951.
52. Light RJ, Pillemer DB. Summing Up - the Science of Reviewing Research. Cambridge, Mass: Harvard University Press; 1984.
53. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638-641.
54. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.
55. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
56. Yussuf S, Peto R, Lewis J, Collins R, Sleigh P. Beta-blockade during and after myocardial infarction: an overview of the randomized clinical trials. Prog Cardiovasc Dis. 1985;27:335-371.
57. Chalmers TC, Blum A, Buyse M, Hewitt P, Koch M, eds. Data Analysis for Clinical Medicine: the Quantitative Approach to Patient Care in Gastroenterology. Rome, Italy: International University Press; 1988.
58. Messori A, Rampazzo R. Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Methods Programs Biomed. 1993;40:261-267.
59. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
60. Jaesche R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? a systematic overview and meta-analysis. Am J Med. 1990;88:179-186.
61. Gabriel SE, Jaakimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787-796.
62. Fries JF, McShane DJ. ARAMIS (American Rheumatism Association Medical Information System). West J Med. 1986;145:798-804.
63. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol. 1986; 14:841-845.
64. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? a review and metaanalysis. J Clin Gastroenterol. 1993;17: 238-243.
65. Ivey KJ. Pathophysiology of NSAID-induced gastroduodenal damage: epidemiology and mechanisms of action of therapeutic agents. Aliment Pharmacol Ther. 1991;5(suppl 1):95-98.
66. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749-754.
67. Knill Jones R, Drummond M, Kohli H, Davies L Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs Postgrad Med J. 1990;66:639-646.
68. Carrin GJ, Tors KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique. 1990;38:187-199.
69. Gabriel S, Jaakkimainen L, Bolley H, Bombardier C. A cost-effectiveness analysis of misoprostol (MS) prophylaxis for NSAID (nonsteroidal anti-inflammatory drug)-induced adverse gastrointestinal (Gl) events. Arthritis Rheum. 1990;33 (suppl):166S. Abstract.
70. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
71. De Pouverville G, Bader J-P. Analyse économique du traitement préventif par le misoprotol chez l'homme des ulcères gastriques liés aux anti-inflammatoires non stéroidiens. Gastroenterol Clin Biol. 1991;15:399-404.
72. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41-47.
73. Hausken T, Stene Larsen G, Lange O, et al. Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive prepyloric changes: a double-blind, placebo-controlled, multicentre study. Scand J Gastroenterol, 1990;25:1028-1033.
74. Herting RL, Clay GA. Overview of clinical safety with misoprostol. Dig Dis. 1985;30 (suppl):185-193S.
75. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
76. Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. Effect of long-term misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study. Gut. 1995;37:195-198.
77. Wallace JL, McNight W, Cirino G, Elliott SN. A nitric oxide-releasing NSAID accelerates gastric ulcer healing. Gastroenterology. 1995;108:252. Abstract.